BRAF and metastatic melanoma: In patients with unresectable metastatic melanoma harboring a BRAF V600E mutation, vemurafenib, a BRAF inhibitor, afforded a higher response rate and longer progression-free survival and overall survival than chemotherapy with dacarbazine [44].